George N. Thalmann

Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial

Nicholas D. James, Matthew R. Sydes, Noel W. Clarke et al. · The Lancet · 2015 · 1.9K citations · Full text

Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial

Christopher Parker, Nicholas D. James, Chris Brawley et al. · The Lancet · 2018 · 1.2K citations · Full text

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

Roland Seiler, H.A.D.M. Ashab, Nicholas Erho et al. · European Urology · 2017 · 775 citations

Urology, Molecular Subtypes, Genitourinary Cancer +8

Radical Cystectomy for Bladder Cancer Today—A Homogeneous Series Without Neoadjuvant Therapy

Stephan Madersbacher, Werner Hochreiter, Fiona C. Burkhard et al. · Journal of Clinical Oncology · 2003 · 753 citations

Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer.

George N. Thalmann, Ploutarchos Anezinis, Shi Chang et al. · PubMed · 1994 · 739 citations

Urology, Oncology, Lncap Model +14